Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service hysterectomy, hysteroscopy & ablation cases in Colorado: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (238 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 1,123 | 46% |
| 2020 | 6 | 905 | 48% |
| 2021 | 6 | 995 | 50% |
| 2022 | 8 | 1,146 | 53% |
| 2023 | 5 | 1,096 | 55% |
| 2024 | 11 | 1,230 | 57% |
| 2025 from claims | – | 1,252 1,149–1,324 | 57% |
| 2026 forecast | – | 1,338 1,177–1,544 | 56% |
| 2027 forecast | – | 1,394 1,192–1,662 | 56% |
| 2028 forecast | – | 1,453 1,213–1,779 | 57% |
| 2029 forecast | – | 1,514 1,237–1,899 | 57% |
| 2030 forecast | – | 1,578 1,264–2,022 | 57% |
Laparoscopic/robotic hysterectomy, hysteroscopic resection, endometrial ablation. Professional codes (what the surgeon bills): CPT 58571, 58573, 58558, 58563, 58353, 58356, 58661, 58662.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 94% of the cases CMS names in Colorado; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 4% inpatient hospital, 88% hospital outpatient, 5% surgery center, 3% office.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 85 | 6,904+1.6%/yr | +1.6%/yr | 2.3 | 25% | 7,960 in 2030+2.4%/yr |
| Arizona | 21 | 1,973+0.3%/yr | +0.3%/yr | 2.9 | 22% | 2,360 in 2030+3%/yr |
| Washington | 21 | 1,715−1.7%/yr | −1.7%/yr | 2.4 | 4% | 2,300 in 2030+5%/yr |
| Oregon | 10 | 1,031+0.7%/yr | +0.7%/yr | 2.7 | 14% | 1,100 in 2030+1.1%/yr |
| Nevada | 3 | 560−0.8%/yr | −0.8%/yr | 2.1 | 20% | 610 in 2030+1.5%/yr |
| Idaho | 5 | 440+2.5%/yr | +2.5%/yr | 2.4 | 9% | 690 in 2030+7.8%/yr |
| New Mexico | 5 | 427−0.8%/yr | −0.8%/yr | 2.0 | 16% | 400 in 2030−1.2%/yr |
| Montana | 7 | 426+5.8%/yr | +5.8%/yr | 2.4 | 8% | 720 in 2030+9.1%/yr |
| Utah | 2 | 384−2.1%/yr | −2.1%/yr | 1.9 | 11% | 380 in 2030−0.1%/yr |
| Alaska | 2 | 275+7.4%/yr | +7.4%/yr | 2.3 | 26% | 220 in 2030−3.5%/yr |
| Hawaii | 2 | 214+5.1%/yr | +5.1%/yr | 1.9 | 14% | 220 in 2030+0.1%/yr |
| Wyoming | 0 | 120+2.1%/yr | +2.1%/yr | 1.1 | 20% | 140 in 2030+2.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 49 | 2,851−4%/yr | −4%/yr | 5.81.3× | 43% | 2,530 in 2030−2%/yr |
| Kidney stone management | 50 | 2,035+0.6%/yr | +0.6%/yr | 4.21.2× | 23% | 2,670 in 2030+4.6%/yr |
| Incontinence, prolapse & sacral neuromodulation | 21 | 1,253+1.4%/yr | +1.4%/yr | 2.61.4× | 19% | 1,570 in 2030+3.8%/yr |
| Prostatectomy & nephrectomy | 9 | 636−1.1%/yr | −1.1%/yr | 1.41.2× | 0% | 690 in 2030+1.4%/yr |
Hysterectomy, hysteroscopy & ablation in every state, and its device makers · Every procedure market in Colorado · Every state · Compare with California
Hologic Sales And Service leads with 85% of company spending on these surgeons in 2025, −4 pts on 2024.
In 2025, 6 companies reported engagement with Colorado’s surgeons worth $19K in consulting, speaking, meals and travel tied to these products, about $1,731 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.